We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Radiation Oncologist Concerns About Increased Electronic Brachytherapy Use for Skin Cancer—Reply

Eleni Linos, MD, DrPH1; Marta VanBeek, MD, MPH2,3; Jack S. Resneck Jr, MD1,4
[+] Author Affiliations
1Department of Dermatology, University of California San Francisco School of Medicine, San Francisco
2Department of Dermatology, University of Iowa, Iowa City
3Department of Epidemiology, University of Iowa, Iowa City
4Philip R. Lee Institute for Health Policy Studies, University of California San Francisco School of Medicine, San Francisco
JAMA Dermatol. 2015;151(9):1037. doi:10.1001/jamadermatol.2015.2007.
Text Size: A A A
Published online


In Reply We thank our colleagues at the American Society for Therapeutic Radiology and Oncology (ASTRO) for their letter supporting our Viewpoint on the sudden and concerning rise in use of electronic brachytherapy (EBT).1 Both the American Academy of Dermatology (AAD) position statement2 and ASTRO’s letter clearly show that major national specialty societies are putting quality care and patient safety first—and that speaks well of the house of medicine and its professional organizations.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





September 1, 2015
Bruce G. Haffty, MD; David C. Beyer, MD; Brian D. Kavanagh, MD, MPH
1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick2Rutgers Robert Wood Johnson Medical School, State University of New Jersey, New Brunswick
3Arizona Oncology Services Physicians, Phoenix
4Department of Radiation Oncology, University of Colorado School of Medicine, Denver
JAMA Dermatol. 2015;151(9):1036. doi:10.1001/jamadermatol.2015.2006.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...